Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine

Abstract

Background

Psychiatric problems have been commonly reported in patients with migraine. This study investigated the reliability and validity of the Generalized Anxiety Disorder-7 (GAD-7) and Generalized Anxiety Disorder-2 (GAD-2) in patients with migraine.

Methods

Subjects were recruited from a headache clinic and a neuropsychologist examined their GAD using the Mini International Neuropsychiatric Interview-Plus Version 5.0.0 (MINI). Subjects completed several instruments, including the GAD-7, the Beck Anxiety Inventory (BAI), the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test-6 (HIT-6), and the Migraine-Specific Quality of Life (MSQoL).

Results

Among 146 participants, 32 patients (21.9 %) had GAD as determined by the MINI. Cronbach's [alpha] for the GAD-7 and GAD-2 were 0.915 and 0.820, respectively. At a cutoff score of 5, the GAD-7 had a sensitivity of 78.1 %, a specificity of 74.6 %, a positive predictive value (PPV) of 46.3 %, and a negative predictive value (NPV) of 92.4 %. At a cutoff score of 1, the GAD-2 had a sensitivity of 84.4 %, a specificity of 72.8 %, a PPV of 46.6 %, and a NPV of 94.3 %. The scores of the GAD-7 and GAD-2 well correlated with the BAI score, the MIDAS score, the HIT-6 score, and the MSQoL score.

Conclusions

The GAD-7 and GAD-2 are both reliable and valid screening instruments for GAD in patients with migraine.

Seo and Park The Journal of Headache and Pain (2015) 16:97

DOI 10.1186/s10194-015-0583-8

RESEARCH ARTICLE Open Access

http://crossmark.crossref.org/dialog/?doi=10.1186/s10194-015-0583-8&domain=pdf

Web End = Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine

Jong-Geun Seo and Sung-Pa Park*

Abstract

Background: Psychiatric problems have been commonly reported in patients with migraine. This study investigated the reliability and validity of the Generalized Anxiety Disorder-7 (GAD-7) and Generalized Anxiety Disorder-2 (GAD-2) in patients with migraine.

Methods: Subjects were recruited from a headache clinic and a neuropsychologist examined their GAD using the Mini International Neuropsychiatric Interview-Plus Version 5.0.0 (MINI). Subjects completed several instruments, including the GAD-7, the Beck Anxiety Inventory (BAI), the Migraine Disability Assessment Scale (MIDAS), the Headache Impact Test-6 (HIT-6), and the Migraine-Specific Quality of Life (MSQoL).

Results: Among 146 participants, 32 patients (21.9 %) had GAD as determined by the MINI. Cronbachs for the GAD-7 and GAD-2 were 0.915 and 0.820, respectively. At a cutoff score of 5, the GAD-7 had a sensitivity of 78.1 %, a specificity of 74.6 %, a positive predictive value (PPV) of 46.3 %, and a negative predictive value (NPV) of 92.4 %. At a cutoff score of 1, the GAD-2 had a sensitivity of 84.4 %, a specificity of 72.8 %, a PPV of 46.6 %, and a NPV of 94.3 %. The scoresof the GAD-7 and GAD-2 well correlated with the BAI score, the MIDAS score, the HIT-6 score, and the MSQoL score.

Conclusions: The GAD-7 and GAD-2 are both reliable and valid screening instruments for GAD in patients with migraine.

Keywords: Anxiety, Migraine, GAD-7, GAD-2, Validity

Background

Migraine is a common and often disabling neurological disorder. In a systemic review of population-based studies, the overall prevalence of migraine worldwide was 11 %, with prevalence rates of 6 % in males and 14 % in females [1]. Migraine represents a public health problem with an enormous burden to both individual patients and society [2].

Psychiatric problems have been commonly reported in patients with migraine. In a Korean hospital-based study,36.3 % of patients with migraine had depression and23.1 % revealed anxiety by self-report questionnaires [3].

In an Italian multicenter study, 23.1 % of patients with migraine exhibited major depressive disorder (MDD)

and 18.4 % exhibited generalized anxiety disorder (GAD) as classified by a structured interview and the Mini International Neuropsychiatry Interview (MINI) [4].

Psychiatric comorbidity complicates the management of patients with headache, and the prognosis for headache treatment is poor [5]. Comorbid psychiatric disorders in patients with migraine affect the frequency and intensity of migraine attacks [6, 7]. In patients with episodic migraine, the presence of psychiatric disorders, such as anxiety or depression or both, facilitate the evolution of the headache into the chronic form [8]. Patients with migraine, anxiety, and chronic depression also had poor health-related quality of life (QOL) [9]. Among psychiatric disorders, anxiety is a common psychiatric comorbidity in patients with migraine [1013]. Anxiety, more than depression, predicts long-term migraine persistence, headache-related disability and reduces perceptions of efficacy with acute treatment [14]. Therefore, the early

* Correspondence: mailto:[email protected]

Web End [email protected] Department of Neurology, School of Medicine, Kyungpook National University, 680 Gukchaebosang-ro, Daegu 700-842, Jung-gu, Republic of Korea

2015 Seo and Park. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/

Web End =http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Seo and Park The Journal of Headache and Pain (2015) 16:97 Page 2 of 7

diagnosis and treatment of anxiety is important for the proper management of patients with migraine. For these purposes, a simple, rapid screening instrument to detect anxiety is a prerequisite, especially in a busy clinical setting.

The Generalized Anxiety Disorder-7 (GAD-7) was developed in the USA as a valuable screening tool for detecting GAD in primary care patients [15]. The Generalized Anxiety Disorder-2 (GAD-2) is a short version of the tool that is composed of the first two questions of the GAD-7 [16]. Both the GAD-7 and GAD-2 have been widely used by general practitioners [16]. Although the GAD-7 and GAD-2 were validated in primary care patients, their usefulness in patients with migraine is unknown. Recently, the Patient Health Questionnaire-9 (PHQ-9) was validated for detecting a MDD in patients with migraine [17]. However, the cutoff score of the PHQ-9 was different from previous studies which were conducted in primary care patients. Likewise the PHQ-9, it is needed to validate the GAD-7 and GAD-2 in patients with migraine. Therefore, this study investigated the reliability and validity of the GAD-7 and GAD-2 as screening tools in patients with migraine.

Methods

SubjectsSubjects in this study were new patients with migraine who had consecutively visited a outpatients headache clinic in the Department of Neurology at Kyungpook National University Hospital from December 2014 to May 2015. Patients were adolescents and adults (aged 1665 years old) who were newly diagnosed at our clinic or were already diagnosed but had not taken triptans, preventive medicines, or other neuropsychiatric agents within the last month. A diagnosis of migraine was based on the International Classification of Headache Disorders, 3rd edition, beta version [18]. Patients were excluded if they were unable to cooperate in the psychiatric interview or had difficulty understanding the questionnaire because of illiteracy, mental retardation, serious medical, neurological, or psychiatric disorders, and alcohol or drug abuse. Patients with a probable migraine and those declining the interview were also excluded.

Study designA cross-sectional study was conducted as part of a hospital-based study that examined the impact of psychiatric disorders on migraine and migraine-associated medications, such as triptans and preventive medicines. The Institutional Review Board of Kyungpook National University Hospital approved the study. All participants gave written informed consent. Subjects medical charts were reviewed to collect demographic, social, and clinical information for a computerized database. Sociodemo-graphic data included age, gender, education, employment,

household income (earning at least three million KRW per month, equivalent to 2800 USD per month or not), and marital status (married or unmarried, divorced, and bereaved). Clinical data included the type of migraine, age at onset, disease duration, attack frequency, attack duration, family history, and accompanying symptoms (presence of photophobia, phonophobia, or osmophobia). A family history of migraine was defined as an existing diagnosis of migraine in a lineal ascendant and/or siblings. Photophobia, phonophobia, and osmophobia were defined as hypersensitivity to light, sound, and certain odors during migraine attacks that could cause avoidance of those stimulations or aggravation of migraine symptoms. Patients were asked whether they experienced symptoms during the preceding year.

To measure the reliability of the GAD-7 and GAD-2 in eligible subjects, one neuropsychologist examined their GAD using the Mini International Neuropsychiatric Interview-Plus Version 5.0.0 (MINI) [19]. Subsequently, patients provided several self-reported questionnaires, including the Beck Anxiety Inventory (BAI) [20], the Korean version of the Migraine Disability Assessment Scale (MIDAS) [21], the Headache Impact Test-6 (HIT-6) [22], and the Migraine-Specific Quality of Life (MSQoL) [23], to examine the validity of the GAD-7 and GAD-2.

Interview and questionnairesMini International Neuropsychiatric Interview-Plus Version5.0.0 (MINI)

The MINI-Plus 5.0.0 is an internationally validated brief structured interview that is used extensively as a diagnostic tool for psychiatric disorders from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition and the International Classification of Diseases-10. The reliability and validity of this instrument is well established[24], and the Korean translation is also validated [19].

Generalized Anxiety Disorder-7 (GAD-7) and Generalized Anxiety Disorder-2 (GAD-2)

The GAD-7 and GAD-2 were designed for use in primary care patients [15, 16]. The GAD-7 consists of a self-report questionnaire that allows for the rapid detection of GAD[15]. Subjects are asked if they were bothered by anxiety related problems over the past two weeks by answering seven items on a 4-point scale. The total scores ranged from 0 to 21. At a cutoff score of 9, the GAD-7 had a sensitivity of 89 % and a specificity of 82 % for detecting GAD compared with a structured psychiatric interview[15]. The GAD-2 is a short version of the tool that is composed of the first two questions of the GAD-7 [16]. At a cutoff score of 2, the GAD-2 had a sensitivity of 86 % and a specificity of 83 % for detecting GAD [16]. The GAD-7 was translated into the Korean language, and was freely downloadable on the Patient Health Questionnaire

Seo and Park The Journal of Headache and Pain (2015) 16:97 Page 3 of 7

website (http://www.phqscreeners.com

Web End =www.phqscreeners.com) [25]. The translated version was translated back into English by a Korean English teacher. Finally, the two versions were compared by a native English speaker who concluded that they were identical. Thereafter, we administered it to 20 Korean PWE for the evaluation of potential problems in comprehension or cultural differences. No further adaptations were required.

Beck Anxiety Inventory (BAI)

The BAI is a 21-item self-report measure of anxiety severity. The scale consists of 21 items, each describing a common symptom of anxiety. The respondent is asked to rate how much he or she has been bothered by each symptom over the past week on a 4-point scale from 0 to 3. The following cutoff points were used: 021, normal; 2226, mild disturbance; 2731, moderate disturbance; and 3263, severe disturbance. The Korean version of the BAI has been validated [20]. Those who scored more than 21 points on the BAI were considered to have anxiety symptoms. Cronbachs was 0.9.

Migraine Disability Assessment Scale (MIDAS)

The Korean version of the MIDAS, a 5-item questionnaire that was designed to evaluate disability during the previous three months, was used in this study [21]. Patients were asked to report decreased performance in the domains of work/school, household work, and family/social activities. Scores (027) measure the overall level of disability: Grade I (05), Grade II (610), Grade III (1120), and Grade IV (above 21). Cronbachs was0.75.

Headache Impact Test-6 (HIT-6)

The HIT-6 was developed in the United States to measure a wider spectrum of headache-induced burden [26]. Items in the HIT-6 cover several domains: pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress. Each item is answered on a 5-point Likert scale (6 = never, 8 = rarely, 10 = sometimes, 11 = very often, 13 = always). The total scores ranged from 36 to 78; larger scores indicate a greater impact. For interpretation, HIT-6 scores are categorized in four groups: scores 49 indicate little or no impact, scores between 50 and 55 indicate some impact, scores between 56 and 59 indicate a substantial impact, and scores 60 indicate a severe impact [27]. The Korean version of the HIT-6 was validated and Cronbachs was 0.85 [22].

Migraine-Specific Quality of Life (MSQoL)

The MSQoL developed by Wagner et al. and is a valid and reliable tool for clinical migraine research [28]. A Korean translation of this 25-item questionnaire has been validated [23]. The items are rated on a 4-point scale (14).

The total scores ranged from 25 to 100. A lower total score indicates a poorer QOL. Cronbachs was 0.93.

Statistical analysesThe Statistical Package for the Social Sciences (SPSS version 21.0) was used for data analysis. The Med Calc 8.0 was used to perform receiver operating characteristic (ROC) analyses to measure sensitivity, specificity, positive predictive values (PPVs) and negative predictive values (NPVs) for a range of cutoff scores of the GAD-7 and GAD2 with respect to the diagnoses of GAD by the MINI-Plus 5.0.0. Optimal cutoff scores were also computed using criteria that minimize the Euclidean distance from point (sensitivity and specificity) to point in the x-y plane. The descriptive statistics are presented as counts, percentages, means, and standard deviations. Independent t-tests, Mann-Whitney U tests, and Chi-square tests were used to compare continuous or categorical variables. Cronbachs was computed to ascertain internal consistency and was recalculated after items were removed. Nonparametric correlations (Spearmans ) were used to determine the validity of the GAD-7 and GAD-2. The level of statistical significance was set at p < 0.05.

Results

Of the 207 patients who consecutively visited a headache clinic, 61 were excluded because of probable migraine (n = 23), taking preventive medicine for migraine or psychotropic agents (n = 10), illiteracy (n = 6), age older than 70 (n = 4), and refusal to take part in the study (n = 18). The 146 remaining patients were eligible for this study. According to the MINI, 32 patients (21.9 %) were diagnosed with GAD. The relationships between GAD and demographic, clinical, and psychosocial characteristics are listed in Table 1. There were no significant differences in demographic characteristics. Among clinical characteristics, patients with GAD were more likely to have a phonophobia; this likelihood was statistically significant. Patients with GAD exhibited significantly higher scores on the GAD-7, the BAI, and the HIT-6, a lower score on the MSQoL than those without GAD.

The subjects completed the GAD-7 without any difficulties in comprehending and replying to the questions. Cronbachs for the GAD-7 and GAD-2 were0.915 and 0.820, respectively, indicating excellent internal consistency. As shown in Table 2, all of the items in the GAD-7 were significantly and positively associated with the total GAD-7 score, and did not decrease if items were deleted. The ROC analyses of the GAD-7 and GAD-2 are shown in Table 3, and the ROC curves are illustrated in Fig. 1. The ROC analysis of the GAD-7 exhibited an area under the curve (AUC) of 0.849 (95 % CI = 0.7750.923; SE = 0.038; p < 0.001). At a cutoff score of >5, the GAD-7 sensitivity was 78.1 % and specificity was 74.6 %,

Seo and Park The Journal of Headache and Pain (2015) 16:97 Page 4 of 7

Table 1 Demographic, clinical, and psychosocial characteristics of the eligible subjects with respect to current GAD as determined by the MINI-Plus 5.0.0

Mean SD (range) or number (%)

No GAD GADCharacteristics (n = 114) (n = 32) p value* Age, years 40.7 13.0 (1665) 37.3 12.8 (1761) 0.195

Gender, female 101 (88.6) 25 (78.1) 0.128 Education, years 12.9 2.8 (518) 12.8 2.8 (616) 0.877 Job, yes 45 (39.5) 15 (46.9) 0.452 Household income, at least 3 million KRW/month 77 (67.5) 19 (59.4) 0.390 Married without divorce or bereavement 72 (63.2) 18 (56.3) 0.478 Age at onset, years 30.5 12.3 (859) 29.1 12.6 (1154) 0.570 Disease duration, years 10.2 8.3 (036) 8.3 7.9 (133) 0.239 Attack frequency/3 months 16.0 18.5 (190) 22.8 24.9 (390) 0.160 Attack duration, hours 26.4 21.8 (472) 30.1 21.7 (472) 0.395 Migraine chronicity, chronic 64 (56.1) 20 (62.5) 0.520 Family history of migraine 70 (61.4) 21 (65.6) 0.663 Photophobia 49 (43.0) 18 (56.3) 0.183 Phonophobia 67 (58.8) 26 (81.3) 0.019 Osmophobia 55 (48.2) 17 (53.1) 0.626 GAD-7 score 3.7 3.4 (015) 10.2 5.4 (121) <0.001 BAI score 9.8 7.1 (035) 25.3 14.7 (256) <0.001 MIDAS, day 23.0 29.3 (0190) 36.5 41.3 (0183) 0.092 HIT-6 score 57.7 7.6 (4072) 63.9 6.3 (4878) <0.001 MSQoL 70.1 15.3 (3494) 54.8 15.3 (2685) <0.001

GAD Generalized Anxiety Disorder, MINI-Plus 5.0.0 Mini International Neuropsychiatric Interview-Plus Version 5.0.0, KRW Korean Won, GAD-7 Generalized Anxiety Disorder-7, BAI Beck Anxiety Inventory, MIDAS Migraine Disability Assessment Scale, HIT-6 Headache Impact Test-6, MSQoL Migraine-Specific Quality of Life *Independent t-test or chi-square tests were performed for the comparison of variables

with a PPV of 46.3 % and an NPV of 92.4 %. The ROC analysis of the GAD-2 exhibited an AUC of 0.842 (95 % CI = 0.7630.920; SE = 0.040; p < 0.001). At a cutoff score >1, the GAD-2 sensitivity was 84.4 with a specificity of72.8 %, a PPV of 46.6 %, and a NPV of 94.3 %.

The validity of the GAD-7 and GAD-2 are shown in

Table 4. The GAD-7 score is well correlated with the BAI score (p < 0.001), the MIDAS score (p < 0.001), the

HIT-6 score (p < 0.001), and the MSQoL score (p < 0.001). The GAD-2 score was also well correlated with the BAI score (p < 0.001), the MIDAS score (p = 0.022), the HIT-6 score (p < 0.001), and the MSQoL score (p < 0.001).

Discussion

This might be the first study investigating the reliability and validity of the GAD-7 and GAD-2 as screening instruments of anxiety in patients with migraine. The GAD-7 and GAD-2 were easily comprehended and quickly completed by patients. Furthermore, they had excellent internal consistency reliability (Cronbachs =0.915 for the GAD-7 and Cronbachs =0.820 for the GAD-2). The validity of the GAD-7 and GAD-2 was determined by correlation with scores from the BAI, the MIDAS, the HIT-6, and the MSQoL.

Many validation studies have been conducted for patients in primary care and hospital settings. The GAD-7 and GAD-2 have been validated in different populations and patient groups [15, 16, 2931]. The initial validation study for the GAD-7, conducted in primary care patients, had a Cronbachs of 0.92, a sensitivity of 89 %, and a

Table 2 Corrected item-total correlations and Cronbachs when an item is deleted from the GAD-7

Corrected item-total

correlation

Cronbachs if

an item deleted Item 1 0.770 0.899

Item 2 0.824 0.893 Item 3 0.772 0.900 Item 4 0.718 0.905 Item 5 0.750 0.903 Item 6 0.722 0.904 Item 7 0.659 0.911

GAD-7 Generalized Anxiety Disorder-7

Seo and Park The Journal of Headache and Pain (2015) 16:97 Page 5 of 7

Table 3 The ROC analyses of the GAD-7 and GAD-2 for the diagnosis of current GAD as determined by the MINI-Plus 5.0.0Cut off score Sensitivity Specificity PPV NPV AUC SE 95 % CI p value GAD-7

> 3 90.6 57.0 37.2 95.6 0.738 0.045 0.6510.826 <0.001 > 4 84.4 67.5 42.2 93.9 0.760 0.046 0.6690.850 <0.001 > 5 78.1 74.6 46.3 92.4 0.763 0.049 0.6680.859 <0.001 > 6 65.6 81.6 50.0 89.4 0.736 0.054 0.6310.841 <0.001 > 7 59.4 87.7 57.6 88.5 0.735 0.056 0.6260.845 <0.001 GAD-2

> 0 93.8 46.5 33.0 96.4 0.701 0.046 0.6110.791 0.001 > 1 84.4 72.8 46.6 94.3 0.786 0.045 0.6980.874 <0.001 > 2 53.1 89.5 58.6 87.2 0.713 0.058 0.6000.826 <0.001

ROC reveiver operating characteristic, GAD-7 Generalized Anxiety Disorder-7, GAD-2 Generalized Anxiety Disorder-2, GAD Major Depressive Disorder, MINI-Plus 5.0.0 Mini International Neuropsychiatric Interview-Plus Version 5.0.0, PPV positive predictive value, NPV negative predictive value, AUC area under the curve

specificity of 82 % at a cutoff score of 9 [15]. In a Finnish study that was conducted in health centers, the sensitivity was 100 % and the specificity was 82.6 % with a cutoff score of 7 or more [29]. In a Spanish hospital-based study, the GAD-7 had a Cronbachs of 0.936, a sensitivity of86.8 and a specificity of 93.4 % at a cutoff score of 9 [30]. In a Dutch population-based study, the GAD-7 had a Cronbachs of 0.86, a sensitivity of 83 % and a specificity of 65 % at a cutoff score of 12 or greater [31]. While the reliability in our study is consistent with these reports, the sensitivity was lower and the specificity was higher than the Dutch study at the lower cutoff score [31].

The GAD-2 has not been as frequently validated as the GAD-7. The first 2 items of the GAD-7 can be useful when an ultra-brief screening tool is desired. The initial GAD-2 validation study was conducted on primary care patients, and reported a sensitivity of 86 % and specificity of 83 % at a cutoff score of 3 or greater[16]. In a Finnish study that was conducted in health

centers, the sensitivity was 83 % and the specificity was 90 % with a cutoff score of 3 or more [29]. In a Dutch population-based study, the GAD-2 had a sensitivity of 83 % and specificity of 61 % at a cutoff score of 4 or greater [31]. In our study, the sensitivity was similar and the specificity was lower than the Dutch study at the lower cutoff score [31].

The cutoff scores in the validation studies of the GAD-7 and GAD-2 in several countries were different from each other with respect to each studys settings and language [15, 16, 2931]. Our study showed that at a cutoff scores of 5 in the GAD-7 and 1 in the GAD-2 had the highest sum of sensitivity and specificity. Cutoff scores were all lower than in previous studies. This suggests that the GAD-7 and GAD-2 validation should be performed for each study settings and specific disease groups. For example, a validation study of the GAD-7 for patients with

Sensitivity

Table 4 Correlation between the GAD-7 and GAD-2 scores and the BAI score, the MIDAS score, the HIT-6 score, and the MSQoL score

Variable r p value* GAD-7

BAI 0.756 <0.001 MIDAS 0.231 <0.001 HIT-6 0.403 <0.001 MSQoL 0.378 <0.001 GAD-2

BAI 0.732 <0.001 MIDAS 0.189 0.022 HIT-6 0.336 <0.001 MSQoL 0.310 <0.001

GAD-7 Generalized Anxiety Disorder-7, GAD-2 Generalized Anxiety Disorder-2, BAI Beck Anxiety Inventory, MIDAS Migraine Disability Assessment Score, HIT-6 Headache Impact Test-6, MSQoL Migraine-Specific Quality of Life *Spearman correlations are applied

GAD-7 GAD-2

1-Specificity

Fig. 1 Receiver operating characteristic curves of the Generalized

Anxiety Disorder-7 and Generalized Anxiety Disorder-2

Seo and Park The Journal of Headache and Pain (2015) 16:97 Page 6 of 7

epilepsy in the Korea reported that a cutoff score of 6 was appropriate for detecting GAD [32]. Differences in the cutoff score may also be related to different interpretations of grading using the Likert scale according to the language difference. For example, a rapid screening instrument for detecting MDD in people with epilepsy, the Neurological Disorders Depression Inventory for Epilepsy, had different cutoff scores when it was validated in different languages[33]. Given these possibilities, it is necessary to validate the GAD-7 and GAD-2 according to different language.

There are several limitations in this study. First, the sample size of the study was small. This may caused a difference in the sensitivity and specificity compared with other studies. Second, the GAD-7 and GAD-2 consist of a self-report questionnaire. These screening instruments only provide a probable diagnosis of GAD that should be investigated by further evaluation. Third, with a cutoff score of 5 in the GAD-7 and a cutoff score of 1 in the GAD-2, the PPVs were 46.3 and 46.6 %, respectively, which may lead to false-positive results. The GAD-7 measures anxiety related problems over the past two weeks. However, the MINI interview investigates GAD over the past 6 months. Because of the difference in the observation period between the two instruments, a low PPVs of the GAD-7 and GAD-2 may exist. Fourth, the GAD-7 and GAD-2 focus on only 1 anxiety disorder, although there are many types of anxiety disorders that require clinical attention. Fifth, this study validated the Korean version of the GAD-7 and GAD-2 in Korean patients with migraine, and their diagnostic properties may be different from those in other languages and countries.

Conclusions

Anxiety is a common psychiatric comorbidity in patients with migraine. Screening for anxiety in patients with migraine can be an effective method to recognize previously unidentified cases of anxiety. The GAD-7 and GAD-2 are simple screening instruments for detecting GAD in patients with migraine. The timely identification of anxiety in patients with migraine is important, as is proper management after diagnosis.

AbbreviationsAUC: area under the curve; BAI: Beck Anxiety Inventory; GAD: generalized anxiety disorder; HIT: Headache Impact Test; MDD: major depressive disorder; MIDAS: Migraine Disability Assessment Scale; MINI: Mini International Neuropsychiatric Interview; MSQoL: Migraine-Specific Quality of Life;

NPVs: negative predictive values; PHQ: Patient Health Questionnaire;

PPVs: positive predictive values; QOL: quality of life; ROC: receiver operating characteristic.

Competing interestsThe authors declare that they have no competing interests.

Authors contributionsSPP took part in the design of the study, contributed to the data collection. JGS and SPP participated in writing the manuscript. JGS was responsible for data statistics. All authors agreed to accept equal responsibility for the

accuracy of the content of the paper. Both authors read and approved the final manuscript.

AcknowledgementsThe authors thank Ju-Hui Lee, a neuropsychologist, for conducting the MINI-Plus 5.0.0 and helping in the completion of self-report questionnaires.

FundingThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Received: 3 October 2015 Accepted: 19 November 2015

References1. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA (2007) The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27:193210

2. Hamelsky SW, Lipton RB, Stewart WF (2005) An assessment of the burden of migraine using the willingness to pay model. Cephalalgia 25:871003. Kim SY, Park SP (2014) The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study. J Headache Pain 15:68

4. Beghi E, Bussone G, DAmico D, Cortelli P, Cevoli S, Manzoni GC, Torelli P, Tonini MC, Allais G, De Simone R, DOnofrio F, Genco S, Moschiano F, Beghi M, Salvi S (2010) Headache, anxiety and depressive disorders: the HADAS study. J Headache Pain 11:141150

5. Pompili M, Serafini G, Di Cosimo D, Dominici G, Innamorati M, Lester D, Forte A, Girardi N, De Filippis S, Tatarelli R, Martelletti P (2010) Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatr Dis Treat 6:8191

6. Sareen J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB (2006) Disability and poor quality of life associated with comorbid anxiety disorders and physical conditions. Arch Intern Med 166:21092116

7. Lantri-Minet M, Radat F, Chautard MH, Lucas C (2005) Anxiety and depression associated with migraine: influence on migraine subjects disability and quality of life, and acute migraine management. Pain 118:319326

8. Mongini F, Ciccone G, Deregibus A, Ferrero L, Mongini T (2004) Muscle tenderness in different headache types and its relation to anxiety and depression. Pain 112:5964

9. Hung CI, Wang SJ, Yang CH, Liu CY (2008) The impacts of migraine, anxiety disorders, and chronic depression on quality of life in psychiatric outpatients with major depressive disorder. J Psychosom Res 65:135142

10. Merikangas KR, Angst J, Isler H (1990) Migraine and psychopathology: results of the Zurich cohort study of young adults. Arch Gen Psychiatry 47:849853

11. Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB (2013) Psychiatric comorbidities of episodic and chronic migraine. J Neurol 260:19601969

12. Jette N, Patten S, Williams J, Becker W, Wiebe S (2008) Comorbidity of migraine and psychiatric disordersa national population-based study. Headache 48:501516

13. McWilliams LA, Goodwin RD, Cox BJ (2004) Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain 111:7783

14. Bellini B, Arruda M, Cescut A, Saulle C, Persico A, Carotenuto M, Gatta M, Nacinovich R, Piazza FP, Termine C, Tozzi E, Lucchese F, Guidetti V (2013) Headache and comorbidity in children and adolescents. J Headache Pain 14:79

15. Spitzer RL, Kroenke K, Williams JB, Lwe B (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166:10921097

16. Kroenke K, Spitzer RL, Williams JB, Monahan PO, Lwe B (2007) Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection. Ann Intern Med 146:317325

17. Seo JG, Park SP (2015) Validation of the Patient Health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with migraine. J Headache Pain 16:6518. Headache Classification Committee of the International Headache Society (2013) The International Classification of Headache Disorders. 3rd edition (beta version). Cephalalgia 33:629808

Seo and Park The Journal of Headache and Pain (2015) 16:97 Page 7 of 7

19. Yoo SW, Kim YS, Noh JS, Oh KS, Kim CH, Namkoong K, Chae JH, Lee GC, Jeon SI, Min KJ, Oh DJ, Joo EJ, Park HJ, Choi YH, Kim SJ (2006) Validity of Korean version of the MINI-International Neuropsychiatric Interview. Anxiety Mood 2:5055

20. Yook SP, Kim ZS (1997) A clinical study on the Korean version of Beck Anxiety Inventory: comparative study of patient and non-patient. Korean J Clin Psychol 16:185197

21. Lee HS, Chung CS, Song HJ, Park HS (2000) The reliability and validity of the MIDAS (Migraine Disability Assessment) Questionnaire for Korean migraine sufferers. J Korean Neurol Assoc 18:287291

22. Chu MK, Im HJ, Ju YS, Yu KH, Ma HI, Kim YJ, Kim J, Lee BC (2009) Validity and reliability assessment of Korean Headache Impact Test-6 (HIT-6).

J Korean Neurol Assoc 27:16

23. Moon HS, Chung CS, Lee HS, Park HS, Kim SW, Woo HW (2003) The reliability and validity of the migraine-specific quality of life questionnaire for Korean migraine suffers. J Korean Neurol Assoc 21:146155

24. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(suppl 20):S22S33

25. Pfizer. Patient Health Questionnaire (PHQ) screeners. http://www.phqscreeners.com/

Web End =http://www. http://www.phqscreeners.com/

Web End =phqscreeners.com/ . [accessed Nov 2012].

26. Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, Cady R, Dahlf CG, Dowson A, Tepper S (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 12:963974

27. Bayliss M, Batenhorst A (2002) The HIT-6 a users guide. Quality Metric Incorporated, Lincoln

28. Wagner TH, Patrick DL, Galer BS, Berzon RA (1996) A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache 36:484492

29. Kujanp T, Ylisaukko-Oja T, Jokelainen J, Hirsikangas S, Kanste O, Kyngs H, Timonen M (2014) Prevalence of anxiety disorders among Finnish primary care high utilizers and validation of Finnish translation of GAD-7 and GAD-2 screening tools. Scand J Prim Health Care 32:7883

30. Garca-Campayo J, Zamorano E, Ruiz MA, Pardo A, Prez-Pramo M, Lpez-Gmez V, Freire O, Rejas J (2010) Cultural adaptation into Spanish of the Generalized Anxiety Disorder-7 (GAD-7) scale as a screening tool. Health Qual Life Outcomes 8:8

31. Donker T, van Straten A, Marks I, Cuijpers P (2011) Quick and easy self-rating of Generalized Anxiety Disorder: validity of the Dutch web-based GAD-7, GAD-2 and GAD-SI. Psychiatry Res 188:5864

32. Seo JG, Cho YW, Lee SJ, Lee JJ, Kim JE, Moon HJ, Park SP (2014) Validation of the generalized anxiety disorder-7 in people with epilepsy: a MEPSY study. Epilepsy Behav 35:5963

33. Zis P, Gatzonis S (2014) Estimating the diagnostic value of the neurological disorders depression inventory for Epilepsy in different languages. Epilepsia 55:941

Submit your manuscript to a journal and benet from:

7 Convenient online submission7 Rigorous peer review7 Immediate publication on acceptance7 Open access: articles freely available online 7 High visibility within the eld7 Retaining the copyright to your article

Submit your next manuscript at 7 springeropen.com